Canada Pension Plan CEO resigns after travelling for vaccine

TORONTO (AP) — The chief executive of the fund that manages Canada Pension Plan investments has resigned after it was revealed that he had traveled to the United Arab Emirates, where he was vaccinated against COVID-19.

CPP Investments said Friday Mark Machin tendered his resignation to the board Thursday night.

Machin joined CPP Investments in 2012 and was appointed president and chief executive in June 2016. Prior to joining the pension fund manager, he spent 20 years at investment bank Goldman Sachs. CPP manages more than 470 billion Canadian dollars in investments on behalf of Canadians.

The Wall Street Journal first reported that Machin flew to the United Arab Emirates this month and received the first dose of the Pfizer-BioNTech vaccine and is awaiting the second dose.

Canadian officials have advised against all nonssential travel and the vast majority of Canadians have not yet been vaccinated

The CPP Investments board has appointed John Graham as the new CEO. Graham was previously its global head of credit investments

Should you invest $1,000 in The Goldman Sachs Group right now?

Before you consider The Goldman Sachs Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and The Goldman Sachs Group wasn't on the list.

While The Goldman Sachs Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
The Goldman Sachs Group (GS)
4.6066 of 5 stars
$418.80-1.0%2.63%16.35Moderate Buy$434.93
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Biotech Boom: Stocks Skyrocketing & What's Next

Biotech Boom: Stocks Skyrocketing & What's Next

Dive into biotech's latest trends with Dylan Jovine: weight loss breakthroughs, smart chemo innovations, and expert stock evaluation tips.

Search Headlines: